Genetic Disorders Partnering Terms and Agreements

Published: August 2014
No. of Pages: 942
   

"Delivery of this report will take 1-3 days after purchase."

The Genetic Disorders Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter genetic disorders partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest genetic disorders deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this report provide an orientation of genetic disorders dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genetic disorders dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading genetic disorders deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of genetic disorder deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all genetic disorder partnering deals signed and announced since 2009. The chapter is organized by specific genetic disorder therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all genetic disorders partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in genetic disorders partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genetic disorders technologies and products.

Benefits

Genetic Disorders Partnering Terms and Agreementsprovides the reader with the following key benefits:

  • In-depth understanding of genetic disorders deal trends since 2009
  • Access genetic disorders deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between genetic disorders partner companies
  • Comprehensive access to links to actual genetic disorders deals entered into by the world’s biopharma companies
  • Indepth review of genetic disorders deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner genetic disorders opportunities
  • Uncover companies actively partnering genetic disorders opportunities

Report scope

Genetic Disorders Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to genetic disorders trends and structure of deals entered into by leading companies worldwide.

Genetic Disorders Partnering Terms and Agreements includes:

  • Trends in genetic disorders dealmaking in the biopharma industry since 2009
  • Analysis of genetic disorders deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to genetic disorders deal contract documents
  • Comprehensive access to genetic disorders deal records
  • The leading genetic disorders deals by value since 2009
  • Most active genetic disorders dealmakers since 2009

In Genetic Disorders Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Genetic Disorders Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in genetic disorders dealmaking
2.1. Introduction
2.2. Genetic disorders partnering over the years
2.3. Bigpharma genetic disorders dealmaking activity
2.4. Bigpharma not active in genetic disorders
2.5. Genetic disorders partnering by deal type
2.6. Genetic disorders partnering by industry sector
2.7. Genetic disorders partnering by stage of development
2.8. Genetic disorders partnering by technology type
2.9. Genetic disorders partnering by dermatology indication
2.10. Average deal terms for genetic disorders
2.10.1 Genetic disorders headline values
2.10.2 Genetic disorders upfront payments
2.10.3 Genetic disorders milestone payments
2.10.4 Genetic disorders royalty rates

Chapter 3 – Leading genetic disorders deals
3.1. Introduction
3.2. Top genetic disorders deals by value
3.3. Top genetic disorders deals involving bigpharma

Chapter 4 – Bigpharma genetic disorders deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma hospital care partnering company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bristol-Myers
Squibb C
elgene
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
GlaxoSmithKline
Hospira
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Pfizer
Roche
Sanofi
Shionogi
Shire
Teva
Warner Chilcott
Watson

Chapter 5 – Genetic disorders partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Joint venture
Licensing
Litigation
Loan
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
5.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
5.4. By technology type
Antibodies
Assays
Biologicalcompounds
Biomaterials
Clinical testing
Devices
Diagnostics
DNA probes
Drug delivery
Enabling technology
Equipment
Genomics
Natural product
Oligonucleotide
Orphan drug
Peptides
Processes
Recombinant DNA
Regenerative medicine
Research services
Research supplies
Screening
Small molecules
Stem cells

Chapter 6 – Genetic disorders dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Genetic disorders
Huntington''s disease
Down''s syndrome
Cystic fibrosis
Sickle cell
Neurofibromatosis
Fragile X syndrome
Hereditary angiodema
Other genetic disorders

Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Directory of genetic disorders deals by company A-Z 2009-2014
Appendix 2 – Directory of genetic disorders deals by deal type 2009-2014

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 3 - Directory of Genetic disorders deals by stage of development 2009-2014
Appendix 4 – Directory of Genetic disorders deals by technology type 2009 - 2014
Appendix 5 – Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Figures

Figure 1: Genetic disorders partnering since 2009
Figure 2: Bigpharma – top 50 – genetic disorders deals 2009 to 2014
Figure 3: Bigpharma genetic disorders deal frequency – 2009 to 2014
Figure 4: Inactive bigpharma in genetic disorders 2009-2014
Figure 5: Genetic disorders partnering by deal type since 2009
Figure 6: Genetic disorders partnering by industry sector since 2009
Figure 7: Genetic disorders partnering by stage of development since 2009
Figure 8: Genetic disorders partnering by technology type since 2009
Figure 9: Genetic disorders partnering by dermatology target since 2009
Figure 10: Genetic disorders deals with a headline value
Figure 11: Genetic disorders deal headline value distribution, US$million – discovery stage
Figure 12: Genetic disorders deal headline value distribution, US$million – preclinical stage
Figure 13: Genetic disorders deal headline value distribution, US$million – phase I stage
Figure 14: Genetic disorders deal headline value distribution, US$million – phase II stage
Figure 15: Genetic disorders deal headline value distribution, US$million – phase III stage
Figure 16: Genetic disorders deal headline value distribution, US$million – regulatory stage
Figure 17: Genetic disorders deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2009-2014
Figure 19: Genetic disorders deals with upfront payment values
Figure 20: Genetic disorders deal upfront payment distribution, US$million – discovery stage
Figure 21: Genetic disorders deal upfront payment distribution, US$million – preclinical stage
Figure 22: Genetic disorders deal upfront payment distribution, US$million – phase I stage
Figure 23: Genetic disorders deal upfront payment distribution, US$million – phase II stage
Figure 24: Genetic disorders deal upfront payment distribution, US$million – phase III stage
Figure 25: Genetic disorders deal upfront payment distribution, US$million – regulatory stage
Figure 26: Genetic disorders deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2009-2014
Figure 28: Genetic disorders deals with milestone payments
Figure 29: Genetic disorders deal milestone distribution, US$million – discovery stage
Figure 30: Genetic disorders deal milestone distribution, US$million – preclinical stage
Figure 31: Genetic disorders deal milestone distribution, US$million – phase I stage
Figure 32: Genetic disorders deal milestone distribution, US$million – phase II stage
Figure 33: Genetic disorders deal milestone distribution, US$million – phase III stage
Figure 34: Genetic disorders deal milestone distribution, US$million – regulatory stage
Figure 35: Genetic disorders deal milestone distribution, US$million – marketed stage
Figure 36: Genetic disorders deals with royalty rates, %
Figure 37: Genetic disorders deal royalty rate distribution, US$million – discovery stage
Figure 38: Genetic disorders deal royalty rate distribution, US$million – preclinical stage
Figure 39: Genetic disorders deal royalty rate distribution, US$million – phase I stage
Figure 40: Genetic disorders deal royalty rate distribution, US$million – phase II stage
Figure 41: Genetic disorders deal royalty rate distribution, US$million – phase III stage
Figure 42: Genetic disorders deal royalty rate distribution, US$million – regulatory stage
Figure 43: Summary median royalty rate by stage of development, 2009-2014
Figure 44: Top genetic disorders deals by value since 2009
Figure 45: Top genetic disorders deals signed by bigpharma value since 2009
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering98


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100